Friedlander, M., Rau, J., Lee, C. K., Meier, W., Lesoin, A., Kim, J. -., Poveda, A., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M. T., Debruyne, P., Bologna, A., Malander, S., Monk, B. J., Petru, E., Calvert, P., Herzog, T. J., Barrett, C., & du Bois, A. (2018). quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. Annals of oncology, 29, 737–743. http://access.bl.uk/ark:/81055/vdc_100095514415.0x000039